The first biotech was upgraded to Strong Buy at Zack’s and the second was just named in the Top 6 IBD 50 Drugmakers.
Biogen Idec Inc (BIIB)
Jazz Pharmaceuticals (JAZZ)
from US Investment Report
Based in Cambridge, MA, Biogen Idec Inc (BIIB) is approaching$10 billion in worldwide sales of therapies for neurodegenerative, hematologic and autoimmune diseases. After a three-year rise from 100 to 350 BIIB plunged to 275 last spring but has worked back to 343—with a target of 390-400 on recently raised sales and earnings guidance.
Updated from ID 750, October 23, 2013
Subscribers will recall the whirlwind 2013 rise of Jazz Pharmaceuticals (JAZZ), a Dublin-based specialty biopharma stock from 50 to 175 last March. It slumped to 125, rebounded to 165 this summer, slumped again to 132, and now is back to 163. With 22% earnings growth, enhanced by a 37% gain this year, and a PEG of just 0.81, a target of 190 is reachable.
Stephen Quickel, U.S. Investment Report, www.usinvestmentreport.com, 215-862-0399, September 5, 2014